Prodrugs pp 1289-1297 | Cite as

Case Study: Moexipril Hydrochloride: A Prodrug of Moexiprilat

  • Bianca M. Liederer
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


Moexiprilat is an orally active, nonsulfhydryl, long-acting dipeptide angiotensin-converting enzyme (ACE) inhibitor used to lower blood pressure (Stimpel et al., 1995; Brogden and Wiseman, 1998; Chrysant and Chrysant, 2003). Moexipril hydrochloride shows improved bioavailability compared to moexiprilat, most likely because esterification reduces the charge of the molecule and the pKa of its amine group (pKa Moexprilat = 7.7; pKa Moexipril = 5.4). Based on the comparable oral bioavailabilities of various esters of enalapril with different lipophilicities, it appears that lipophilicity is not the only factor that enhances oral bioavailability (Wyvratt and Patchett, 1985).


Severe Essential Hypertension Male Human Volunteer Show Maximum Stability Isoquinolinecarboxylic Acid Additional Medical Benefit 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abernethy DR, Fox AA, and Stimpel M. Moexipril in the Treatment of Mild to Moderate Essential Hypertension: Comparison with Sustained-release Verapamil. J Clin Pharmacol 1995; 35:794–799PubMedGoogle Scholar
  2. Brogden RN and Wiseman LR. Moexipril: A Review of its use in the Management of Essential Hypertension. Drugs 1998; 55:845–860PubMedCrossRefGoogle Scholar
  3. Cawello W, Boekens H, Waitzinger J, and Miller U. Moexipril Shows a Long Duration of Action Related to an Extended Pharmacokinetic Half-life and Prolonged ACE Inhibition. Int J Clin Pharmacol Ther 2002; 40:9–17PubMedGoogle Scholar
  4. Chrysant SG, and Chrysant GS. Pharmacological Profile and Clinical Use of Moexipril. Expert Rev Cardiovasc Ther 2003; 1:345–352PubMedCrossRefGoogle Scholar
  5. Drayer JI, Stimpel M, Fox A, and Weber M. The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic. Am J Ther 1995; 2:525–531PubMedCrossRefGoogle Scholar
  6. Edling O, Bao G, Feelisch M, Unger T, and Gohlke P. Moexipril, a New Angiotensin-Converting Enzyme (ACE) Inhibitor: Pharmacological Characterization and Comparison with Enalapril. J Pharmacol Exp Ther 1995;275:854–863PubMedGoogle Scholar
  7. Friehe H, and Ney P. Pharmacological and Toxicological Studies of the New Angiotensin-converting Enzyme (ACE) Inhibitor Moexipril Hydrochloride. Arzneimittelforschung 1997; 47:132–144PubMedGoogle Scholar
  8. Grass GM, and Morehead WT. Evidence for Site-specific Absorption of a Novel ACE Inhibitor. Pharm Res 1989; 6:759–765PubMedCrossRefGoogle Scholar
  9. Gu L, and Strickley RG. Diketopiperazine Formation, Hydrolysis, and Epimerization of the New Dipeptide Angiotensin-converting Enzyme Inhibitor RS-10085. Pharm Res 1987; 4:392–397PubMedCrossRefGoogle Scholar
  10. Gu L, and Strickley RG. Preformulation Stability Studies of the New Dipeptide Angiotensin-converting Enzyme Inhibitor RS-10029. Pharm Res 1988;5:765–771PubMedCrossRefGoogle Scholar
  11. Gu L, Strickley RG, Chi LH, and Chowhan ZT. Drug-excipient Incompatibility Studies of the Dipeptide Angiotensin-converting Enzyme Inhibitor, Moexipril Hydrochloride: Dry Powder vs Wet Granulation. Pharm Res 1990; 7:379–383PubMedCrossRefGoogle Scholar
  12. Hoefle ML, and Klutchko S. Substituted Acyl Derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acids. US Patent 4,344,949, August 17, 1982Google Scholar
  13. Klutchko S, Blankley CJ, Fleming RW, Hinkley JM, Werner AE, Nordin I, Holmes A, Hoefle ML, Cohen DM, Essenburg AD, and Kaplan HR. Synthesis of Novel Angiotensin Converting Enzyme Inhibitor Quinapril and Related Compounds. A Divergence of Structure-Activity Relationships for Non-Sulfhydryl and Sulfhydryl Types. J Med Chem 1986; 29:1953–1961PubMedCrossRefGoogle Scholar
  14. Lucas CP, Darga LL, Fox AA, and Stimpel M. A Study of the Efficacy and Safety of Moexipril in Mild to Moderate Hypertension. Am J Ther 1995; 2:886–892PubMedCrossRefGoogle Scholar
  15. Pines A, and Fisman EZ. ACE Inhibition with Moexipril: A Review of Potential Effects Beyond Blood Pressure Control. Am J Cardiovasc Drugs 2003; 3:351–360PubMedCrossRefGoogle Scholar
  16. Stimpel M, Bonn R, Koch B, and Dickstein K. Pharmacology and Clinical Use of the new ACE-Inhibitor Moexipril. Cardiovasc Drug Rev 1995; 13:211–229CrossRefGoogle Scholar
  17. Stimpel M, Koch B, Jansen T, Fox A, and Loh I. Moexipril versus Captopril in Patients with Mild to Moderate Hypertension. J Cardiovasc Pharmacol 1996;28:769–773PubMedCrossRefGoogle Scholar
  18. Strickley RG, Visor GC, Lin LH, and Gu L. An Unexpected pH Effect on the Stability of Moexipril Lyophilized Powder. Pharm Res 1989; 6:971–975PubMedCrossRefGoogle Scholar
  19. Unger T, and Gohlke P. Converting Enzyme Inhibitors in Cardiovascular Therapy: Current Status and Future Potential. Cardiovasc Res 1994; 28:146–158PubMedCrossRefGoogle Scholar
  20. White CM. Pharmacologic, Pharmacokinetic, and Therapeutic Differences among ACE Inhibitors. Pharmacotherapy 1998; 18:588–599PubMedGoogle Scholar
  21. White WB, Fox AA, and Stimpel M. Long-term Efficacy and Safety of Moexipril in the Treatment of Hypertension. J Hum Hypertens 1994; 8:917–921PubMedGoogle Scholar
  22. White WB, Koch B, and Stimpel M. Usefulness of Moexipril and Hydrochlorothiazide in Moderately Severe Essential Hypertension. Am J Ther 1997; 4:123–129PubMedCrossRefGoogle Scholar
  23. White WB, and Stimpel M. Long-term Safety and Efficacy of Moexipril Alone and in Combination with Hydrochlorothiazide in Elderly Patients with Hypertension. J Hum Hypertens 1995; 9:879–884PubMedGoogle Scholar
  24. Wyvratt MJ, and Patchett AA. Recent Developments in the Design of Angiotensin-Converting Enzyme Inhibitors. Med Res Rev 1985; 5:483–531PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Bianca M. Liederer
    • 1
  1. 1.Department of Pharmaceutical ChemistryThe University of KansasLawrenceUSA

Personalised recommendations